on 18 Jan 2022
Last Applicant/ Owned by
Emil-von-Behring Str. 76
Marburg
DE
D-35041
Serial Number
90398064 filed on 21st Dec 2020
Registration Number
6618400 registered on 18th Jan 2022
Correspondent Address
Scott D. Woldow
SMITH, GAMBRELL & RUSSELL, LLP
1055 THOMAS JEFFERSON STREET, NW
SUITE 400
WASHINGTON, DC, , , , 20007
Filing Basis
No Filing Basis
Disclaimer
NO DATA
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bRead More
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE
No 90398064
No Service/Collective Mark
No 034845.253
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
18th Jan 2022 | REGISTERED-PRINCIPAL REGISTER |
02th Nov 2021 | PUBLISHED FOR OPPOSITION |
02th Nov 2021 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
13th Oct 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
29th Sep 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
29th Sep 2021 | EXAMINER'S AMENDMENT ENTERED |
29th Sep 2021 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
29th Sep 2021 | EXAMINERS AMENDMENT E-MAILED |
29th Sep 2021 | EXAMINERS AMENDMENT -WRITTEN |
27th Sep 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |